Sign in

Patrick Durisch

@dbdurisch.bsky.social
194 followers 129 following 35 posts

Health Policy - Politique Santé Public Eye (formerly the Berne Declaration) www.publiceye.ch

PostsRepliesMedia
Patrick Durisch @dbdurisch.bsky.social · 18/06/2026
Swiss House rejects EFTA-Mercosur free trade deal www.swissinfo.ch/eng/agribusi...
swissinfo.ch
Swiss House rejects EFTA-Mercosur free trade deal
The Swiss House of Representatives has rejected the free trade deal between EFTA and Mercosur.
000
Reposted by Patrick Durisch
Global Investigative Journalism Network @gijn.org · 15/06/2026
💊 ICIJ found in its yearlong project involving 124 journalists across 37 countries, that pharmaceutical giant Merck's pricing and patent strategies for its cancer drug Keytruda drive up costs and limit patient access to the life-saving treatment. twp.ai/9OXmcX
0810
Reposted by Patrick Durisch
Corporate Europe Observatory (CEO) @corporateeurope.org · 11/06/2026
Welcome to EU Corporate Lobby League 2026 where big money = big influence Today we will reveal: 🏭 Biggest corporate lobby sectors ✂️ Their lobby agenda to cut our protections 💪 What we can do about it By Corporate Europe Observatory & @lobbycontrol.bsky.social corporateeurope.org/en/2026/06/e...
Cover graphic for The EU's 2026 Corporate Lobby League. A large illustrated trophy emitting smoke and euro symbols stands on a platform flanked by oil barrels and a drilling rig. To the right, the top five ranked sectors are listed: 1. Big Tech, 2. Banking & Finance, 3. Energy, 4. Chemicals & Agri-Business, 5. Cross-Sector, each with a corresponding icon. Logos of Corporate Europe Observatory and Lobby Control appear at the bottom.
13337
Reposted by Patrick Durisch
Public Eye @publiceye.ch · 04/06/2026
Wir lehnen die revidierte #KVV Vorlage zu Medikamentenpreisen in der Schweiz ab. Die Einsparungen werden gering bleiben, solange nichts gegen die Machtasymmetrie zwischen #Pharma & BAG unternommen wird. Es braucht eine gründlichere Reform und mehr Transparenz! www.publiceye.ch/de/news/deta...
publiceye.ch
Überarbeitung des Systems zur Medikamenten­preisfestsetzung: ...
Mit Massnahmen zur Dämpfung der Gesundheitskosten hat das Parlament Geheimrabatte für Medikamente gesetzlich verankert. Nun werden diese und weitere Gesetzesänderungen auf Verordnungsebene k...
134
Patrick Durisch @dbdurisch.bsky.social · 03/06/2026
@fr.publiceye.ch rejette le projet de révision #OAMal sur le prix des médicaments en 🇨🇭. Les économies resteront modestes tant qu'on n'agira pas sur l'asymétrie de pouvoir entre #pharma et @bag.admin.ch. Il faut une réforme plus drastique & davantage de transparence ! www.publiceye.ch/fr/news/deta...
publiceye.ch
Révision du système de fixation du prix des médicaments : des éco...
Le Parlement avait décidé de légaliser les rabais secrets sur les médicaments dans le cadre de la modification de la loi sur l’assurance-maladie (LAMal) afin de freiner la hausse des coûts d...
100
Reposted by Patrick Durisch
Tahir Amin @tahiramin.bsky.social · 28/05/2026
It was a pleasure to speak with Aisha Nyandoro for @forbes.com on the occasion of the U.S release of Pharma Monopoly. www.forbes.com/sites/aishan...
forbes.com
A Former IP Attorney On Why Drug Pricing Is Really About Power
Pharmaceutical monopolies, patent law, and global health access shaping drug pricing, power, and inequities in the U.S. and worldwide.
022
Reposted by Patrick Durisch
Tahir Amin @tahiramin.bsky.social · 27/05/2026
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain. www.statnews.com/2026/05/26/h...
statnews.com
The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
022
Reposted by Patrick Durisch
Page One Media @pageonem.bsky.social · 26/05/2026
Happy publication day, Tahir!  Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY, @tahiramin.bsky.social and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.
123
Reposted by Patrick Durisch
Els Torreele @elstorreele.bsky.social · 08/05/2026
After millions of German and EU subsidies «to create/preserve domestic technological capacity and jobs» BionTech still decides unilaterally to close down factories because it suit their business interests. When will policy makers step up and implement industrial policy in the public interest?
032
Reposted by Patrick Durisch
Philipp Albrecht @phalbrecht.bsky.social · 17/04/2026
Wer zahlt am meisten Steuern in der Schweiz? Normalerweise: Roche, Novartis oder Nestlé. Neu zahlt ein US-Pharmakonzern mehr als alle anderen. Deutlich mehr. Die Recherche von @tikollbrunner.bsky.social und mir mit Unterstützung des @icij.org heute auf @republik.ch www.republik.ch/2026/04/17/g...
republik.ch
Geldregen mit Trumps Segen
Warum ein US-Konzern in der Schweiz mehr Steuern bezahlt als Nestlé und Novartis.
084
Reposted by Patrick Durisch
Timo Kollbrunner @tikollbrunner.bsky.social · 17/04/2026
Switzerland🇨🇭, MSDs💊 favourite (tax💸) holiday destination 🏝️ @icij.org @phalbrecht.bsky.social @republik.ch #CancerCalculus
042
Reposted by Patrick Durisch
Access to Meds | Public Citizen @pcmedsaccess.bsky.social · 15/04/2026
Public Citizen’s Peter Maybarduk told ICIJ that pharma created a system of rules to protect drugmakers and ensure wealthy governments protect them “There is a whole architecture underpinning Keytruda and every patented drug where the US government and Europe go to bat for the industry and its rules”
053
Patrick Durisch @dbdurisch.bsky.social · 15/04/2026
Thank you @tahiramin.bsky.social @imakglobal.bsky.social for supporting @fr.publiceye.ch in our patent analysis of cancer drug #Keytruda, in conjunction with @icij.org, unveiling MSD's gaming of the patent systems to maintain overinflated prices & delay competition www.publiceye.ch/en/topics/ph...
publiceye.ch
A dose of this cancer drug costs more than an ounce of gold
Keytruda, manufactured by the US pharmaceutical giant Merck Sharp & Dohme (MSD), offers genuine hope for cancer patients and oncologists alike. However, it’s also a nightmare for insurers and public h...
22112
Reposted by Patrick Durisch
ICIJ @icij.org · 13/04/2026
#CancerCalculus: An ICIJ-led collaboration with 47 media partners in 37 countries reveals how Merck & Co. keeps the price of its lifesaving cancer drug Keytruda sky-high, locking out patients and squeezing health care systems worldwide. www.icij.org/investigatio...
48051
Reposted by Patrick Durisch
Le Temps @letemps.ch · 13/04/2026
Prix record, brevets en cascade et coûts de recherche contestés: une enquête de l’ONG Public Eye et du Consortium international des journalistes d’investigation révèle comment l’anticancéreux phare de MSD s’est imposé comme...
l.letemps.ch
Keytruda: les dessous d’un médicament star aux marges hors norme
012
Reposted by Patrick Durisch
Philipp Albrecht @phalbrecht.bsky.social · 13/04/2026
Our first—and hopefully not our last—collaboration with our colleagues at the @icij.org ✊🏼 @republik.ch #CancerCalculus
032
Reposted by Patrick Durisch
Timo Kollbrunner @tikollbrunner.bsky.social · 13/04/2026
Zusammen mit @icij.org haben @phalbrecht.bsky.social und ich für die @republik.ch recherchiert, warum die Krebstherapie Keytruda die Welt – und die Schweiz – so viel kostet wie kein anderes Medikament. Und wieso sich daran nichts ändert. #CancerCalculus www.republik.ch/2026/04/13/d...
republik.ch
Das Medikament, das alles sprengt
Kein Arzneimittel kostet die Welt so viel wie die Krebs­therapie Keytruda. Wer profitiert?
032
Reposted by Patrick Durisch
Public Eye Suisse @fr.publiceye.ch · 13/04/2026
💊 En Suisse, le médicament anticancéreux #Keytruda a permis au géant pharmaceutique MSD de réaliser un chiffre d'affaires de 31,7 milliards de dollars en 2025. Notre enquête conjointe avec @icij.org montre comment MSD fait du « patent evergreening »➡️ www.publiceye.ch/fr/keytruda
publiceye.ch
Une dose de cet anticancéreux coûte plus cher qu’une once d’or
Le Keytruda du géant étatsunien Merck Sharp & Dohme (MSD) représente un réel espoir pour les malades du cancer et les oncologues. Il est aussi le cauchemar des assureurs et des budgets de santé publiq...
074
Reposted by Patrick Durisch
Global Trade Watch @pcgtw.bsky.social · 19/02/2026
Read the Principles for Access to Medicines and Trade: www.citizen.org/news/more-th...
citizen.org
More Than 100 Organizations Urge Countries to Resist Trump’s Trade Attacks, Protect Access to Affordable Medicines - Public Citizen
WASHINGTON, D.C. — Public Citizen, Health GAP, and 99 expert organizations from around the world are calling for an approach…
016
Reposted by Patrick Durisch
Global Trade Watch @pcgtw.bsky.social · 19/02/2026
The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines. Experts from around the world offer an alternate vision:
Teal background, highlighted quote: "Pro-corporate, pro-monopoly models reinforced by the current trade order and exploited by the powerful are failing the world. Health must be a guarantee, not a bargaining chip."

Blue background with caption: Over 100 organizations around the world detail principles for trade that ensure access to medicines."
12616
Patrick Durisch @dbdurisch.bsky.social · 04/02/2026
"Pharmaceutical companies are raising prices elsewhere instead of bringing them down in the US, due to rules introduced by President Donald Trump that force drugmakers to reduce their prices in the US to the lowest level paid in other developed countries." www.bloomberg.com/news/article...
bloomberg.com
Trump’s Attempt to Make Drugs Cheaper Is Pushing Up Prices in Other Countries
The president’s order is upending health care in Switzerland.
100
Reposted by Patrick Durisch
Peter Maybarduk @maybarduk.bsky.social · 03/02/2026
Trump says he lowered drug prices. We’ll believe it when we see it. So we sued for access to the secret deals.
021
Patrick Durisch @dbdurisch.bsky.social · 29/01/2026
"Die Basler drohen der 🇨🇭 mit Jobabbau und dem Zurückhalten ihres neuen «revolutionären» Brustkrebsmedikaments." Eine Frechheit von #Roche als sie fast 14 Milliarden Franken Reingewinn im 2025 machten. Erpressen & jammern, das können sie weiterhin gut🤔 www.tagesanzeiger.ch/roche-droht-...
tagesanzeiger.ch
Wegen Trump: Neues Brustkrebsmedikament könnte Schweizer Kassen sprengen
Giredestrant soll zum neuen Standard bei Brustkrebs werden. Wegen des US-Deals muss Roche den Preis der Therapie vielleicht anheben. Und zwar so stark, dass ihn Krankenkassen nicht mehr erstatten könnten.
121
Patrick Durisch @dbdurisch.bsky.social · 29/01/2026
Alors que le lobby pharma ne cesse de se lamenter sur les vélléités 🇺🇸 (inoffensives pour l'instant) de baisser le prix des médicaments, le géant bâlois #Roche annonce des bénéfices nets de CHF 13,8 milliards en 2025 ! Ça va, il y a encore de la marge (bénéficiaire) 🤔 www.publiceye.ch/fr/regard/de...
publiceye.ch
Deals des pharmas suisses aux États-Unis: une farce au goût amer
Peu avant Noël, les géants bâlois Roche et Novartis ont conclu un « deal » très attendu avec la Maison blanche sur le prix des médicaments aux États-Unis. Contrairement à ce qu’on pourrait croire, le ...
021
Reposted by Patrick Durisch
Public Eye Suisse @fr.publiceye.ch · 28/01/2026
Plainte en diffamation de Kolmar: les autrices et l’auteur d’un rapport de Public Eye et TRIAL ont été acquitté·e·s des charges de « diffamation voire calomnie ». La Cour a balayé l’appel et confirmé la solidité de notre enquête. Un signal fort pour la liberté d’informer ! 👉 peye.link/plainte-kolmar
publiceye.ch
Plainte en diffamation de Kolmar: un second acquittement importan...
Dans le cadre d’une procédure en appel, la justice bernoise a acquitté aujourd’hui des charges de «diffamation voire calomnie» les autrices et l’auteur d’un rapport de Public Eye et TRIAL In...
031
Reposted by Patrick Durisch
Medicines Law & Policy @medslawpolicy.bsky.social · 28/01/2026
Legal tools that lower medicines prices have expanded access to medicines for over two decades, new ML&P research in @bmj.com reveals. Read about study, the most comprehensive review to-date of use of @wto.org IP rules, here: medicineslawandpolicy.org/2026/01/lega...
033
Reposted by Patrick Durisch
Public Eye Suisse @fr.publiceye.ch · 28/01/2026
Conclu peu avant Noël, le « deal » américain de #Roche et #Novartis prévoit des rabais importants, mais sur une quantité réduite de médicaments et pour un nombre limité de patient·e·s. Qui y gagne ? Les actionnaires. @dbdurisch.bsky.social dans #RegardDePublicEye 👉 www.publiceye.ch/fr/regard/de...
publiceye.ch
Deals des pharmas suisses aux États-Unis: une farce au goût amer
Peu avant Noël, les géants bâlois Roche et Novartis ont conclu un « deal » très attendu avec la Maison blanche sur le prix des médicaments aux États-Unis. Contrairement à ce qu’on pourrait croire, le ...
023
Reposted by Patrick Durisch
Public Eye @publiceye.ch · 26/01/2026
Der US-Deal von #Roche & #Novartis: hohe Rabatte – aber nur auf fiktive Listenpreise. Reale Medikamentenkosten bleiben hoch, Big Pharma kassiert Milliarden-Privilegien. Winner: Aktionäre. Loser: Gesundheitssysteme. @dbdurisch.bsky.social in #PublicEyeStandpunkte 👉 www.publiceye.ch/de/standpunk...
publiceye.ch
US-Deal der Schweizer Pharma: eine bittere Farce
Ende letzten Jahres kam es zum mit Spannung erwarteten «Deal» von Roche und Novartis mit dem Weissen Haus über Medikamentenpreise in den USA. Für Patient*innen dies- und jenseits des Atlantiks ist die...
054
Patrick Durisch @dbdurisch.bsky.social · 11/12/2025
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations insights.citeline.com/pink-sheet/l...
insights.citeline.com
Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
142
Patrick Durisch @dbdurisch.bsky.social · 08/12/2025
The $150bn question: has the 🇮🇳 gov considered introducing drug #dataexclusivity on its own, after resisting it for decades in trade talks? Or has 🇨🇭 @SECO_StateSec helped by suggesting it could attract additional foreign investment, as reported by 🇮🇳 press? www.thehindubusinessline.com/news/keep-da...
010
Reposted by Patrick Durisch
Oliver Classen @oliclassen.bsky.social · 18/11/2025
50 years after the baby formula scandal, @publiceye.ch shows that, regarding sugar, a similar malpractice continues. In an open letter, 19 civil society organisations in 13 countries are calling on Nestlé to put an end to inacceptable double standard. www.publiceye.ch/en/topics/cr...
publiceye.ch
Africa’s baby food sugar scandal
Nestlé is exploiting parents’ love and concerns around the world to transform food for small children into a highly lucrative business. But at what price? One and a half years after our first revelati...
078
Patrick Durisch @dbdurisch.bsky.social · 19/11/2025
www.swissinfo.ch/eng/various/...
swissinfo.ch
Nestlé accused of selling high sugar content in Africa
Swiss NGO Public Eye has again accused the Swiss food giant Nestlé of selling over-sugared baby food in Africa.
000
Reposted by Patrick Durisch
The Guardian @theguardian.com · 17/11/2025
Nestlé accused of ’risking health of babies for profit’ over added sugar in cereals sold in African countries
theguardian.com
Nestlé accused of ’risking health of babies for profit’ over added sugar in cereals sold in African countries
Campaigners say the company is contributing to rising rates of childhood obesity, while the firm says it is helping to combat malnutrition Nestlé is still adding sugar to most baby cereals sold across Africa, according to an investigation by campaigners who have accused the company of “putting the health of African babies at risk for profit”. The food firm was accused of “double standards” over the researchers’ findings, which come at a time when rates of childhood obesity are rising on the continent, prompting calls for Nestlé to remove all added sugar from baby-food products. Continue reading...
1516564
Patrick Durisch @dbdurisch.bsky.social · 18/11/2025
www.publiceye.ch/en/media-cor...
publiceye.ch
Sugar scandal: in Africa, Nestlé is still putting profit ahead of...
More than 50 years since the baby formula scandal, a new investigation focusing on Africa shows that, regarding sugar, a similar malpractice continues. In contrast to India where, after our ...
000
Reposted by Patrick Durisch
Public Eye @publiceye.ch · 18/11/2025
Eineinhalb Jahre nach unseren ersten Enthüllungen zeigt eine neue Untersuchung zu Cerelac-Babynahrung, dass #Nestlé auf dem afrikanischen Kontinent Babys weiterhin mit Zucker vollstopft.🍼 Eine Recherche von @laurentgaberell.bsky.social, hier zu lesen 👉 www.publiceye.ch/de/themen/kr...
publiceye.ch
In Afrika verkauft Nestlé weiterhin Babynahrung mit viel zugesetztem Zucker
Aus der Liebe und Fürsorge von Eltern auf der ganzen Welt macht Nestlé ein äusserst profitables Geschäft rund um die Ernährung von Kleinkindern. Aber zu welchem Preis? Anderthalb Jahre nach unserem er...
1169
Reposted by Patrick Durisch
Public Eye Suisse @fr.publiceye.ch · 18/11/2025
Un an et demi après nos premières révélations, une nouvelle enquête sur les céréales infantiles Cerelac montre que Nestlé continue de gaver de sucre les bébés sur le continent africain.🍼 Une enquête de @laurentgaberell.bsky.social à lire ici 👉 www.publiceye.ch/fr/thematiqu...
publiceye.ch
En Afrique, le scandale du sucre dans les aliments pour bébés
Nestlé exploite l’amour et les inquiétudes des parents, aux quatre coins du monde, pour transformer l’alimentation des jeunes enfants en un business très lucratif. Mais à quel prix? Une nouvelle enquê...
021
Reposted by Patrick Durisch
The Guardian @theguardian.com · 18/11/2025
Nestlé accused of ’risking health of babies for profit’ over added sugar in cereals sold in African countries
theguardian.com
Nestlé accused of ’risking health of babies for profit’ over added sugar in cereals sold in African countries
Campaigners say the company is contributing to rising rates of childhood obesity, while the firm says it is helping to combat malnutrition
129733
Patrick Durisch @dbdurisch.bsky.social · 12/11/2025
www.swissinfo.ch/eng/various/...
swissinfo.ch
Switzerland, the benchmark country for US drug prices
The US government is pressing ahead with plans to bring drug prices more into line with those in other countries, including Switzerland.
000
Patrick Durisch @dbdurisch.bsky.social · 06/11/2025
A new study @fr.publiceye.ch shows Roche’s patent "evergreening" strategy for its HER2+ breast cancer drugs (Herceptin & Co), enabling it to rake in >CHF 156 bn & hinder timely access to affordable biosimilars until 2042. 👉 Time for 🇨🇭 to act against patent thickets www.publiceye.ch/en/topics/ph...
publiceye.ch
Abusive pharma patents: Roche’s “mAb” empire
An exclusive tally of Roche’s patent portfolio for its four monoclonal antibodies (“mAb”) treatments for breast cancer shows that, 27 years after the first product hit the market, about 100 patents st...
0108
Patrick Durisch @dbdurisch.bsky.social · 06/11/2025
A new study @fr.publiceye.ch shows Roche’s patent "evergreening" strategy for its HER2+ breast cancer drugs (Herceptin & Co), enabling it to rake in >CHF 156 bn & hinder timely access to affordable biosimilars until 2042. 👉 Time for 🇨🇭 to act against patent thickets www.publiceye.ch/en/topics/ph...
publiceye.ch
Abusive pharma patents: Roche’s “mAb” empire
An exclusive tally of Roche’s patent portfolio for its four monoclonal antibodies (“mAb”) treatments for breast cancer shows that, 27 years after the first product hit the market, about 100 patents st...
020
Reposted by Patrick Durisch
Public Eye @publiceye.ch · 06/11/2025
💊 Neue Recherche: #Roche hält mit über 100 Sekundärpatenten sein Monopol auf Brustkrebstherapien künstlich aufrecht. Dieses sogenannte #Evergreening verhindert günstige Generika, hält Preise hoch und schränkt weltweit den Zugang zu lebenswichtigen Behandlungen ein. www.publiceye.ch/de/themen/ph...
publiceye.ch
Der Missbrauch von Patenten durch Roche gefährdet die Gesundheit
Public Eye hat in einer aufwendigen Pionierstudie die Roche-Patente für seine vier Antikörpertherapien («mAb») gegen Brustkrebs gezählt. Das Resultat: 27 Jahre nach der ersten Markteinführung schützen...
03925
Patrick Durisch @dbdurisch.bsky.social · 14/10/2025
www.livemint.com/companies/ne...
livemint.com
Roche moves Supreme Court against Natco Pharma over sale of generic Risdiplam in India | Company Business News
Roche approached the Supreme Court after the Delhi High Court division bench refused to bar Natco Pharma from selling the generic version of Risdiplam which is used to treat a rare genetic disorder th...
000
Reposted by Patrick Durisch
Thiru Balasubramaniam @thirugeneva.bsky.social · 09/10/2025
spicyip.com
Breaking: DHC Dismisses Roche’s Appeal in the Risdiplam Case
Image from here In a huge development concerning the Risdiplam litigation saga, a division bench of the Delhi High Court has rejected the appeal against the order refusing to grant an interim injun…
001
Reposted by Patrick Durisch
Thiru Balasubramaniam @thirugeneva.bsky.social · 09/10/2025
livemint.com
Delhi HC allows Natco Pharma to sell generic Risdiplam, rejects Roche plea | Company Business News
The division bench upheld the single-judge bench’s findings, which cited public interest in ensuring affordable access to SMA treatment, allowing Natco Pharma to launch a lower-cost generic despite Ro...
001
Reposted by Patrick Durisch
Public Eye @publiceye.ch · 23/09/2025
Unsere neueste Recherche mit @unearthednews.bsky.social zeigt, dass die EU trotz gegenteiliger Versprechen 2024 fast 122’000 Tonnen verbotene #Pestizide in Länder mit niedrigem oder mittlerem Einkommen exportiert hat. #Syngenta gehört zu den wichtigsten Exporteuren. www.publiceye.ch/de/themen/pe...
publiceye.ch
Verbotene Pestizide: Massive Zunahme der Exporte aus der EU
Eine exklusive Recherche von Public Eye und Unearthed zeigt, dass die Europäische Union im Jahr 2024 fast 122’000 Tonnen verbotene Pestizide exportiert hat. Dabei hatte sich die EU-Kommission verpflic...
074
Reposted by Patrick Durisch
Public Eye Suisse @fr.publiceye.ch · 23/09/2025
🔎 Notre nouvelle enquête avec @unearthednews.bsky.social révèle que, malgré ses promesses, l’UE a exporté près de 122’000 tonnes de #pesticides interdits vers des pays à revenus faibles ou intermédiaires en 2024. Syngenta fait partie des principales entreprises exportatrices. 👇
publiceye.ch
Pesticides interdits: les exportations de l’UE en forte hausse
L’Union européenne a exporté près de 122'000 tonnes de pesticides interdits en 2024, alors que la Commission s'était engagée à faire cesser cette pratique. La majorité de ces volumes est destinée à de...
044
Reposted by Patrick Durisch
Pesticide Action Network Europe (PAN Europe) @paneurope.bsky.social · 23/09/2025
1/3 🧵 As this new report by @publiceye.ch reveals, the @ec.europa.eu’s failure to act, due to pressure from the #pesticide industry giants and their profits, has allowed Europe’s toxic trade to grow larger than ever. www.publiceye.ch/en/topics/pe...
publiceye.ch
Banned pesticides
The European Union exported nearly 122,000 tonnes of banned pesticides in 2024, despite a European Commission commitment to put an end to the practice, a new Public Eye and Unearthed investigation has...
1810
Patrick Durisch @dbdurisch.bsky.social · 21/09/2025
www.swissinfo.ch/eng/drug-pri...
swissinfo.ch
Novartis CEO wants to end higher pricing for drugs sold in the US
CEO Vasant Narasimhan believes that countries outside the USA have a duty to contribute more to innovation.
000
Reposted by Patrick Durisch
Health Action International @hai-org.bsky.social · 09/09/2025
As negotiators prepare for talks to clear the final hurdle of the #PandemicAgreement, we remind them that there has never been a better opportunity for the international community to put equity at the heart of pandemic response. haiweb.org/pandemic-agr... @who.int @3rdworldnetwork.bsky.social
haiweb.org
Pandemic Agreement - The Final Hurdle - Health Action International
The adoption of the pandemic agreement at the World Health Assembly earlier this year was hailed by many as a milestone.
022
Reposted by Patrick Durisch
Oliver Classen @oliclassen.bsky.social · 10/09/2025
Schweizer Aussenwirtschaftspolitik ist diskreter als Trumps Zollhammer, dient aber auch der rücksichtslosen Durchsetzung ökonomischer Eigeninteressen. Mein Meinungsbeitrag für @publiceye.ch liefert dafür Beispiele von Big Pharma bis Rohstoffhandel. Darunter leiden v.a. einkommensschwächere Länder.
tagesanzeiger.ch
Wie bei Trump: Das «Geschäftsmodell Schweiz» beruht auf dem Recht des Stärkeren
Trumps Zollhammer zeigt Parallelen zur helvetischen Aussen­wirtschafts­politik. Wie der US-Präsident nutzen auch die hiesigen Branchen ihre globale Machtposition aus.
0148